Linnoila M, Viukari M, Vaisanen K, Auvinen J
Am J Psychiatry. 1980 Jul;137(7):819-21. doi: 10.1176/ajp.137.7.819.
Patients who had therapeutic plasma levels of phenobarbital and/or diphenylhydantoin had significantly lower plasma levels of haloperidol and mesoridazine, the active metabolite of thioridazine, than patients who did not receive anticonvulsants. Plasma thioridazine levels per se were not affected by concomitant anticonvulsant treatment. Biperiden, an antimuscarinic, antiparkinsonian agent, did not affect the plasma levels of these three neuroleptics.
与未接受抗惊厥药物治疗的患者相比，苯巴比妥和/或苯妥英钠血浆水平处于治疗范围的患者，其血浆中氟哌啶醇和硫利达嗪的活性代谢产物美索达嗪的水平显著较低。硫利达嗪本身的血浆水平不受同时使用抗惊厥药物治疗的影响。抗胆碱能、抗帕金森病药物安坦不影响这三种抗精神病药物的血浆水平。
